Omega-3 fatty acid supplements occupy a strange place in UK community pharmacy. For decades, fish oil was a generic "good for your heart" purchase. Then three major cardiovascular outcomes trials — VITAL, REDUCE-IT and STRENGTH — landed within a few years of each other and produced results that directly contradicted the marketing. One trial was clearly negative for general prevention. One was clearly positive for a very specific patient group. One was positive then turned negative when tested more carefully.

Counter advice in 2026 needs to keep these three trials apart. Here is what they showed, who benefits from omega-3 products under the UK system, and where the shelves have run ahead of the evidence.

The three trials that shape 2026 advice

VITAL randomised just under 26,000 US adults over 50 to either 1 g/day of marine omega-3 (EPA + DHA) or placebo, for primary cardiovascular prevention. The primary results published in NEJM were negative for the main composite cardiovascular endpoint, although secondary analyses suggested a reduction in myocardial infarction in some subgroups. Primary-prevention fish oil for a generally healthy adult does not have strong trial backing.

REDUCE-IT randomised 8,179 patients who were already on a statin with elevated triglycerides and established cardiovascular disease (or diabetes with risk factors) to high-dose icosapent ethyl — a purified EPA product — 2 g twice daily, or a mineral-oil placebo. The NEJM paper reported a 25% relative reduction in the primary composite cardiovascular endpoint. This trial was the basis for NICE TA805, which approved icosapent ethyl on the NHS for a narrow, high-risk, statin-treated group with raised triglycerides.

STRENGTH tried to replicate the REDUCE-IT finding using a mixed EPA/DHA formulation (omega-3 carboxylic acids) at 4 g/day in a comparable statin-treated high-risk population, with a corn-oil placebo. The JAMA paper reported no benefit and the trial was stopped early for futility. The discordance between REDUCE-IT and STRENGTH remains actively debated — it may reflect the purified-EPA formulation, the mineral-oil comparator, or both.

What that means for the pharmacy shelf

UK community pharmacy stocks standard fish oil, cod liver oil and own-brand omega-3 capsules. These are not the same product as prescription icosapent ethyl. A pharmacy omega-3 capsule typically contains 300–600 mg of combined EPA/DHA. To replicate the REDUCE-IT regimen from an OTC product would require a handful of capsules twice a day, a dose and cost that very few people sustain.

Three fair counter positions in 2026:

1. Routine omega-3 supplementation in a healthy adult with no cardiovascular risk factors has weak evidence behind it. VITAL was the largest relevant trial and it was negative for the primary endpoint.
2. Two portions of oily fish per week — the NHS recommendation — remains the best-supported dietary pattern and is what cardiovascular guidelines still endorse.
3. High-dose purified EPA (icosapent ethyl) is a prescription product for a specific patient group — statin-treated, high cardiovascular risk, raised triglycerides — not an OTC purchase. Patients asking about it should be directed to their GP.

Triglycerides, not cholesterol

Community pharmacy is used to "cholesterol" being the headline number. Omega-3 products have their clearest effect on triglycerides, not LDL cholesterol.

• Marine omega-3 at 2–4 g/day can lower fasting triglycerides by 20–30% in people with elevated levels.
• LDL cholesterol is unchanged or can rise slightly on some formulations.
• HDL cholesterol changes are modest.

A customer whose cardiovascular risk is driven by LDL — the typical statin-candidate — will not shift their risk meaningfully by buying a box of 1 g fish oil capsules. Statins remain the first-line intervention. The NICE guidance on cardiovascular risk assessment reflects that order of priority.

Pregnancy and child brain development

A persistent claim is that omega-3 in pregnancy improves the baby's brain development. The trial picture is mixed. Some randomised trials have shown small reductions in preterm birth with DHA supplementation in pregnancy, particularly in women with low baseline intake. The effect on the child's later cognitive development is inconsistent across studies.

A defensible pharmacy line: eating oily fish in pregnancy within NHS recommended limits is sensible. Taking a DHA-containing prenatal supplement is reasonable for women who do not eat fish. Avoid cod liver oil in pregnancy because of its vitamin A content. Super-high doses of fish oil are not required.

Bleeding, interactions and AF

Omega-3 has a reputation for thinning the blood. At typical OTC doses, clinically significant bleeding is uncommon. At the 4 g/day trial dose, a small excess of bleeding was seen in REDUCE-IT, and both REDUCE-IT and several meta-analyses have signalled an increased risk of atrial fibrillation with high-dose omega-3.

Points for the counter:

• Inform patients on warfarin, DOACs or antiplatelets if they plan high-dose fish oil — this is a conversation worth flagging to their GP.
• Advise that new-onset palpitations on high-dose omega-3 should trigger a GP review.
• Vitamin A: cod liver oil contains pre-formed retinol. In pregnancy and in large daily doses it is a legitimate concern.
• Fish allergy: most refined fish oils are tolerated, but severe fish-allergic patients should choose an algal-source product.

Further reading on PharmSee

• Vitamin B12 supplements at the pharmacy: cyanocobalamin, methylcobalamin and who needs them
• Zinc at the pharmacy: colds, wound healing and taste
• Blood pressure check at the pharmacy: free NHS service

Explore UK community pharmacies on PharmSee.

Sources and caveats

Content drawn from the published primary reports of REDUCE-IT, STRENGTH and VITAL, the NICE technology appraisal on icosapent ethyl, and NHS guidance on fish intake. Trial evidence remains the subject of active methodological debate. This article is general information for UK community pharmacy use, not personalised medical advice.